Materials architecture for gastric residence systems
The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.
1. A co-extruded elongate member comprising;
at least one carrier polymer-therapeutic agent (or salt thereof);
at least one disintegrating linker, wherein the at least one disintegrating linker is a time-dependent linker and is configured to weaken to cause the elongate member to decouple or weaken; and
a reinforcing material comprising one or more of polycaprolactone (PCL), polydioxanone, polylactic acid, polycarbonate, polyether ether ketone, polyethylene, or polypropylene,
wherein the disintegrating linker comprises PCL, and
wherein the reinforcing material extends axially along the co-extruded elongate member,
wherein said elongate member is configured for use in a stellate gastric residence system having a gastric residence time between about 48 hours and one month.
2. A co-extruded elongate member comprising:
at least two segments, each segment comprising a proximal end, a distal end, and an outer surface therebetween; and
a reinforcing material comprising one or more of polycaprolactone (PCL), polydioxanone, polylactic acid, polycarbonate, polyether ether ketone, polyethylene, or polypropylene,
wherein the at least two segments are attached together via a linker region comprising a disintegrating linker comprising PCL, wherein the at least one disintegrating linker is a time-dependent linker and is configured to weaken to cause the elongate member to decouple or weaken, and
wherein the reinforcing material extends axially along one or more of the at least two segments,
wherein said elongate member is configured for use in a stellate gastric residence system having a gastric residence time between about 48 hours and one month.
3. The elongate member of claim 2 , wherein the disintegrating linker is an enteric linker.
4. The elongate member of claim 2 , wherein the disintegrating linker comprises HPMCAS and PCL in a ratio of between about 80 HPMCAS:20 PCL to about 50 HPMCAS:50 PCL.
5. The elongate member of claim 2 , wherein the disintegrating linker further comprises a plasticizer.
6. The elongate member of claim 5 , wherein the plasticizer comprises triacetin, triethyl citrate, tributyl citrate, poloxamers, polyethylene glycol, polypropylene glycol, diethyl phthalate, dibutyl sebacate, glycerin, castor oil, acetyl triethyl citrate, acetyl tributyl citrate, polyethylene glycol monomethyl ether, sorbitol, sorbitan, a sorbitol-sorbitan mixture, or diacetylated monoglycerides, or mixtures thereof.
7. The elongate member of claim 2 , wherein the segments comprise PCL.
8. The elongate member of claim 4 , wherein the segments comprise PCL.
9. The elongate member of claim 2 , wherein the elongate member has a triangular cross-section with rounded corners and edges.
10. The elongate member of claim 2 , wherein the linker region is about 1 mm to about 2 mm in length.
11. The elongate member of claim 2 , wherein the segments are about 2 mm to about 20 mm in length.
12. The co-extruded elongate member of claim 1 , wherein the reinforcing material extends axially along a single side of the outer surface of the co-extruded elongate member.
13. The co-extruded elongate member of claim 1 , wherein the reinforcing material comprises polycaprolactone without therapeutic agent or salt thereof.
14. The elongate member of claim 2 , wherein the reinforcing material extends axially along a single side of the outer surface of one or more of the at least two segments.
15. The elongate member of claim 2 , wherein the reinforcing material comprises polycaprolactone without therapeutic agent or salt thereof.
16. A gastric residence system comprising an elongate member of claim 2 .
17. A method of manufacturing the elongate member of claim 2 for use in a gastric residence system, comprising:
co-extruding the elongate member.
18. The method of claim 17 , wherein co-extruding the elongate member comprises:
co-extruding a ribbon comprising at least two ribbon strip regions comprising a carrier polymer-therapeutic agent (or salt thereof) blend and at least one ribbon strip region comprising a linker region blend, wherein each ribbon strip region of carrier polymer-agent blend is separated from an adjacent ribbon strip region of carrier polymer-agent blend by a ribbon strip region comprising a linker blend.
19. The method of claim 17 , where co-extruding the elongate member comprises:
co-extruding a ribbon comprising two ribbon strip regions comprising a carrier polymer-therapeutic agent (or salt thereof) blend and a ribbon strip region comprising a linker blend, wherein the two regions of carrier polymer-agent blend are separated by the linker region.
20. The method of claim 19 , further comprising cutting the ribbon in a direction perpendicular to the direction of extrusion to form the elongate member.
21. The method of claim 17 , where co-extruding the elongate member comprises:
co-extruding a ribbon comprising a region comprising a carrier polymer-therapeutic agent (or salt thereof) blend and a region comprising a linker.
22. The method of claim 21 , further comprising cutting the ribbon in a direction perpendicular to the direction of extrusion to form the elongate member.
23. The method of claim 18 , wherein the carrier polymer of the carrier polymer-therapeutic agent (or salt thereof) blend is selected from the group consisting of polycaprolactone and polydioxanone.
24. The method of claim 18 , wherein the therapeutic agent (or salt thereof) of the carrier polymer-therapeutic agent (or salt thereof) blend is selected from the group consisting of analgesics; anti-analgesics; anti-inflammatory drugs; antipyretics; antidepressants; antiepileptics; antipsychotic agents; neuroprotective agents; anti-proliferatives; anti-cancer agents; antihistamines; antimigraine drugs; hormones; prostaglandins; antimicrobials; antibiotics; antifungals; antivirals; antiparasitics; anti-muscarinics; anxiolytics; bacteriostatics; immunosuppressant agents; sedatives; hypnotics; antipsychotics; bronchodilators; anti-asthma drugs; cardiovascular drugs; anesthetics; anti-coagulants; enzyme inhibitors; steroidal agents; steroidal or non-steroidal anti-inflammatory agents; corticosteroids; dopaminergics; electrolytes; gastro-intestinal drugs; muscle relaxants; nutritional agents; vitamins; parasympathomimetics; stimulants; anorectics; anti-narcoleptics; antimalarial drug; quinine; lumefantrine; chloroquine; amodiaquine; pyrimethamine; proguanil; chlorproguanil-dapsone; sulfonamides; sulfadoxine; sulfamethoxypyridazine; mefloquine; atovaquone; primaquine; halofantrine; doxycycline; clindamycin; artemisinin; artemisinin derivatives; artemether; dihydroartemisinin; arteether; and artesunate.
25. The method of claim 18 , wherein the linker region comprises a material selected from the group consisting of an enteric linker and a time-dependent linker.
26. The method of claim 18 , wherein the linker region comprises hydroxypropyl methyl cellulose acetate succinate (HPMC-AS) and polycaprolactone.
27. The method of claim 17 , wherein the co-extruding is at a rate sufficient to prepare between about 30 and about 500 elongate members per minute.
28. The method of claim 17 , wherein the co-extruding is performed at a rate sufficient to produce elongate members between about 5 to about 50 times faster than single-component extrusion at the same linear extrusion rate.
29. The method of claim 18 , wherein at least one junction between a carrier polymer-agent region and a linker region is co-extruded in an interlocking configuration.
30. The method of claim 18 , wherein at least one carrier polymer-agent region is co-extruded in an islands-in-the-sea configuration.
31. The method of claim 18 , wherein at least one linker region is co-extruded in an islands-in-the-sea configuration.
32. The method of claim 30 , wherein the island components of the islands-in-the-sea configuration comprise at least one material selected from the group consisting of an enteric polymer and a time-dependent polymer.
33. The method of claim 18 , wherein the linker regions uncouple after about seven days in fasted-state simulated gastric fluid.
34. The method of claim 17 , wherein co-extruding the elongate member comprises:
co-extruding a carrier polymer-therapeutic agent (or salt thereof) blend and a reinforcing material.